Statins reduce cardiovascular events and cardiovascular and total mortality in persons at
risk for and with coronary disease, but there remains a significant residual event rate,
particularly in those with the atherogenic lipid phenotype that is characterized by a low high-
density lipoprotein (HDL) cholesterol and increase in non-HDL cholesterol. Large outcome
trials designed to assess the value of combining statins with other agents to target HDL
cholesterol and non-HDL cholesterol will not be completed for a few years, but there is …